Xencor’s (XNCR) Outperform Rating Reiterated at BMO Capital Markets

BMO Capital Markets reissued their outperform rating on shares of Xencor (NASDAQ:XNCR) in a report released on Tuesday, Benzinga reports. The brokerage currently has a $32.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on XNCR. BTIG Research cut their target price on Xencor from $56.00 to $38.00 and set a buy rating on the stock in a report on Tuesday, April 16th. Raymond James dropped their price objective on Xencor from $58.00 to $40.00 and set a strong-buy rating on the stock in a research note on Friday, June 14th. JPMorgan Chase & Co. decreased their target price on Xencor from $30.00 to $27.00 and set an overweight rating for the company in a research report on Wednesday, July 31st. Wedbush reaffirmed an outperform rating and set a $34.00 target price (down from $36.00) on shares of Xencor in a research report on Thursday, June 13th. Finally, Royal Bank of Canada decreased their target price on Xencor from $32.00 to $31.00 and set an outperform rating for the company in a research report on Friday, June 14th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $34.44.

Xencor Trading Down 0.1 %

NASDAQ:XNCR traded down $0.02 on Tuesday, reaching $16.04. 348,019 shares of the stock traded hands, compared to its average volume of 638,900. The firm has a market capitalization of $989.03 million, a price-to-earnings ratio of -7.32 and a beta of 0.69. The company’s 50 day moving average is $19.95 and its 200-day moving average is $21.17. The company has a current ratio of 6.92, a quick ratio of 7.08 and a debt-to-equity ratio of 0.02. Xencor has a 1-year low of $15.31 and a 1-year high of $26.84.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The company had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. The business’s quarterly revenue was down 62.7% compared to the same quarter last year. During the same period last year, the business earned ($0.37) EPS. Equities research analysts anticipate that Xencor will post -3.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Xencor news, VP John R. Desjarlais sold 36,329 shares of Xencor stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $665,547.28. Following the completion of the transaction, the vice president now owns 192,319 shares of the company’s stock, valued at approximately $3,523,284.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.23% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Primecap Management Co. CA grew its holdings in Xencor by 0.3% during the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after buying an additional 25,495 shares in the last quarter. Vanguard Group Inc. grew its holdings in Xencor by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after buying an additional 243,793 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after buying an additional 335,881 shares in the last quarter. Armistice Capital LLC boosted its position in shares of Xencor by 1.5% during the 4th quarter. Armistice Capital LLC now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $31,845,000 after acquiring an additional 22,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Xencor by 6.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock valued at $27,628,000 after acquiring an additional 87,979 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.